VRAX NASDAQ
Virax Biolabs Group Limited
1W: -8.3%
1M: -13.7%
3M: -29.3%
YTD: +472.9%
1Y: +255.2%
3Y: -29.0%
$2.20
-0.04 (-1.79%)
Weekly Expected Move ±9.1%
$2
$2
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$12K
+96.2% ▲
5Y CAGR: -36.9%
Gross Profit
$8K
+114.5% ▲
Operating Income
-$6M
-3.8% ▼
Net Income
-$5M
+17.1% ▲
EPS (Diluted)
$-12.64
+74.1% ▲
EBITDA
-$5M
+6.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $0 | $9K | $156K | $6K | $12K |
| YoY Growth | -100.0% | +0.0% | +1727.1% | -96.0% | +96.2% |
| Cost of Revenue | $0 | $10K | $106K | $59K | $5K |
| Gross Profit | $0 | -$1K | $51K | -$53K | $8K |
| Gross Margin | — | -15.9% | 32.3% | -838.2% | 61.9% |
| R&D Expenses | $434K | $397K | $2M | $2M | $4M |
| SG&A Expenses | $1M | $5M | $5M | $4M | $3M |
| Operating Expenses | $2M | $6M | $7M | $6M | $6M |
| Operating Income | -$2M | -$6M | -$6M | -$6M | -$6M |
| Operating Margin | — | -66963.7% | -4153.3% | -97344.8% | -51515.2% |
| Interest Expense | $15K | $15K | $27K | $58K | $62K |
| Income Before Tax | -$2M | -$5M | -$7M | -$6M | -$6M |
| Tax Expense | $0 | $0 | $0 | -$137K | -$900K |
| Net Income | -$2M | -$5M | -$7M | -$6M | -$5M |
| Net Margin | — | -63748.3% | -4304.8% | -95739.2% | -40439.1% |
| EPS (Diluted) | $-1.50 | $-5.13 | $-3.36 | $-1.95 | $-12.64 |
| EBITDA | -$750 | -$5M | -$7M | -$6M | -$5M |
| Shares Outstanding | 1M | 1M | 2M | 3M | 397590 |